BioVex Limited clinical trials
Acquired by Amgen, Mar 4, 2011 · source ↗
The registry lists 6 studies whose lead sponsor is BioVex Limited. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 13, 2016.
Before and after it joined Amgen
- First submitted before BioVex Limited became part of Amgen
- 4
- First submitted after BioVex Limited became part of Amgen
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- BioVex Limited6 studies
Something wrong with this grouping? Tell us on the Amgen page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Amgen studies →
- Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in MelanomaCompletedNCT00769704Phase 3
Sponsor listed in the registry: BioVex Limited · First submitted before BioVex Limited became part of Amgen
- Talimogene Laherparepvec in Patients With Unresectable Pancreatic CancerCompletedNCT00402025Phase 1
Sponsor listed in the registry: BioVex Limited · First submitted before BioVex Limited became part of Amgen
- Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck CancerTerminatedNCT01161498Phase 3
Sponsor listed in the registry: BioVex Limited · First submitted before BioVex Limited became part of Amgen
- An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaCompletedNCT01368276Phase 3
Sponsor listed in the registry: BioVex Limited · First submitted after BioVex Limited became part of Amgen
- A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant MelanomaCompletedNCT00289016Phase 2
Sponsor listed in the registry: BioVex Limited · First submitted before BioVex Limited became part of Amgen
- An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)CompletedNCT02574260Phase 2
Sponsor listed in the registry: BioVex Limited · First submitted after BioVex Limited became part of Amgen